Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index must be between 18.0 kg/m2 and ≤ 31.5 kg/m2;~* Non-smokers for at least 3 months preceding screening;~* Females subjects must be of non-childbearing potential e.g., post-menopausal or pre-menopausal with surgical sterilization;~* Males agree to use appropriate contraception;~* Medical history must be verified by either a personal physician or medical practitioner as appropriate;~* Willing to give written informed consent and are willing to comply with the study requirements.~Exclusion Criteria:~* Known hepatitis B surface antigen (HBsAg), hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection~* Multiple drug allergies or know sensitivity to oligonucleotide~* History of drug abuse and/or alcohol abuse~* Receiving an investigational agent within 3 months prior to study drug administration~* Subjects with safety laboratory test results deemed clinical significant by the Investigator;~* Received prescription drugs within 4 weeks of first dosing~* Subjects who have donated more than 500 mL of blood within the 3 months prior to ALN-PCS02 or placebo administration;~* Subjects who have used prescription drugs within 4 weeks of first dosing~* Considered unfit for the study by the Principal Investigator~* Employee or family member of the sponsor or the clinical study site personnel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- ALN-TTR02 (Type: ACTIVE_COMPARATOR): None
- Sterile Normal Saline (0.9% NaCl) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).